MAP2K3 and colorectal carcinoma: We recently demonstrated the MKK3/MYC crosstalk as a novel molecular mechanism thwarting the therapeutic efficacy of BRAF inhibitors (dabrafenib) in BRAF-mutated CRC, ultimately leading to dabrafenib resistance [11].